Related Experiment Video
Updated: Oct 19, 2025
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
Published on: May 12, 2023
Why are we vaccinating children against COVID-19?
Ronald N Kostoff1, Daniela Calina2, Darja Kanduc3
1Independent Consultant, Gainesville, VA, 20155, USA.
Insights
COVID-19 inoculations for children show a concerning risk-benefit ratio. Post-inoculation deaths in children, though small, are not negligible, raising long-term safety concerns.
Area of Science:
- Pediatric Health
- Infectious Disease Epidemiology
- Vaccine Safety Research
Background:
- COVID-19 mortality is significantly higher in the elderly with comorbidities compared to children.
- Existing clinical trials for pediatric COVID-19 inoculations have limitations in duration, sample size, and population representativeness.
- Long-term effects and biomarker changes post-inoculation in children remain understudied.
Purpose of the Study:
- To critically evaluate the risk-benefit profile of COVID-19 inoculations in pediatric populations.
- To assess the potential long-term implications of pediatric COVID-19 inoculations.
- To compare inoculation-attributed risks versus COVID-19-attributed risks in children.
Main Methods:
- Review of existing COVID-19 mortality data stratified by age.
- Analysis of normalized post-inoculation mortality data.
- A best-case scenario cost-benefit analysis comparing inoculation risks to disease risks.
Main Results:
- COVID-19 attributed deaths per capita are negligible in children.
- Normalized post-inoculation deaths in children are small but not negligible.
- Cost-benefit analysis indicates a significantly higher risk of death from inoculation versus COVID-19 in the elderly (5:1 ratio), suggesting a less favorable ratio for children due to lower COVID-19 risk and unknown long-term effects.
Conclusions:
- The current risk-benefit assessment for pediatric COVID-19 inoculations raises significant concerns due to minimal COVID-19 mortality in this age group and the unknown long-term consequences.
- Further research into long-term safety, biomarker changes, and robust clinical trials with larger, representative pediatric samples are warranted.
- The risk-benefit ratio for pediatric COVID-19 inoculations may be unfavorable, particularly when considering potential long-term adverse effects.
Abstract:
This article examines issues related to COVID-19 inoculations for children. The bulk of the official COVID-19-attributed deaths per capita occur in the elderly with high comorbidities, and the COVID-19 attributed deaths per capita are negligible in children. The bulk of the normalized post-inoculation deaths also occur in the elderly with high comorbidities, while the normalized post-inoculation deaths are small, but not negligible, in children. Clinical trials for these inoculations were very short-term (a few months), had samples not representative of the total population, and for adolescents/children, had poor predictive power because of their small size. Further, the clinical trials did not address changes in biomarkers that could serve as early warning indicators of elevated predisposition to serious diseases. Most importantly, the clinical trials did not address long-term effects that, if serious, would be borne by children/adolescents for potentially decades. A novel best-case scenario cost-benefit analysis showed very conservatively that there are five times the number of deaths attributable to each inoculation vs those attributable to COVID-19 in the most vulnerable 65+ demographic. The risk of death from COVID-19 decreases drastically as age decreases, and the longer-term effects of the inoculations on lower age groups will increase their risk-benefit ratio, perhaps substantially.
Related Concept Videos
01:51Vaccinations
01:26Principles of Disease Surveillance
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:28Criteria for Causality: Bradford Hill Criteria - II
01:29Microorganisms in Medicine and Therapeutics
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...